| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2432e896fd3f306b9de62638568d1d2b |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M11-007
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M15-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M2202-0468 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M11-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M11-007
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0043
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M15-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M11-04 |
| filingDate |
2020-12-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_078fcc680b7b2ddb667c82ffcd1fcff7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1fd5bf279fccf54b7fb5143df0ac6057
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_121ed232c0849772470c20e4be82ce75
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9fda12109a59a7547974131b1ba34eb4 |
| publicationDate |
2022-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2022401439-A1 |
| titleOfInvention |
Intranasal pharmaceutical compositions of cgrp inhibitors |
| abstract |
Provided is pharmaceutical composition for intranasal delivery, wherein the pharmaceutical composition includes a therapeutically active ingredient including a CGRP inhibitor. Also provided is a method for delivering a CGRP inhibitor to a subject, wherein the method includes intranasally administering to the subject a composition including a therapeutically active component including a CGRP inhibitor. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-D1001997-S |
| priorityDate |
2019-12-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |